AR118369A1 - Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva - Google Patents
Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptivaInfo
- Publication number
- AR118369A1 AR118369A1 ARP200100724A ARP200100724A AR118369A1 AR 118369 A1 AR118369 A1 AR 118369A1 AR P200100724 A ARP200100724 A AR P200100724A AR P200100724 A ARP200100724 A AR P200100724A AR 118369 A1 AR118369 A1 AR 118369A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- lymphocytes
- adoptive transfer
- differentiation
- expansion
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 230000004069 differentiation Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000009258 tissue cross reactivity Effects 0.000 abstract 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2317—Interleukin-17 (IL-17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
Método para obtener linfocitos T y células NK con el fenotipo deseado en la transferencia adoptiva de células para la terapia del cáncer. Especialmente, se basa en estrategias para inducir una señalización preferencial a través del receptor de lL2 de afinidad intermedia, con lo cual se logra expandir las células con el fenotipo de memoria central deseado. El método de la presente es útil en la obtención de linfocitos infiltrantes de tumor, TCR o de receptores quiméricos ingenierizados de células T empleados en el tratamiento del cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2019000021A CU20190021A7 (es) | 2019-03-15 | 2019-03-15 | Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118369A1 true AR118369A1 (es) | 2021-09-29 |
Family
ID=72087852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200100724A AR118369A1 (es) | 2019-03-15 | 2020-03-13 | Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220152107A1 (es) |
EP (1) | EP3940063A2 (es) |
JP (1) | JP2022524882A (es) |
KR (1) | KR20220012224A (es) |
CN (1) | CN113785048A (es) |
AR (1) | AR118369A1 (es) |
AU (1) | AU2020242520B2 (es) |
BR (1) | BR112021018100A2 (es) |
CA (1) | CA3133736A1 (es) |
CO (1) | CO2021013127A2 (es) |
CU (1) | CU20190021A7 (es) |
EA (1) | EA202192447A1 (es) |
MX (1) | MX2021011120A (es) |
SG (1) | SG11202109574QA (es) |
TW (1) | TW202102667A (es) |
WO (1) | WO2020187340A2 (es) |
ZA (1) | ZA202107758B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ766453A (en) | 2018-02-01 | 2022-02-25 | Nkmax Co Ltd | Method of producing natural killer cells and composition for treating cancer |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2023004004A1 (en) * | 2021-07-23 | 2023-01-26 | Merck Sharp & Dohme Llc | Il-2 muteins for treating cancer or infection |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1956080E (pt) * | 2005-08-08 | 2011-12-30 | San Raffaele Centro Fond | Uso de il-7 e il-15 para a modificação genética de linfócitos t da memória |
WO2009053109A1 (en) * | 2007-10-24 | 2009-04-30 | Anne Letsch | Antigen-specific t-cell preparations from bone marrow |
CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
US11053293B2 (en) * | 2016-02-05 | 2021-07-06 | Washington University | Compositions and methods for targeted cytokine delivery |
-
2019
- 2019-03-15 CU CU2019000021A patent/CU20190021A7/es unknown
-
2020
- 2020-03-09 CN CN202080020973.5A patent/CN113785048A/zh active Pending
- 2020-03-09 BR BR112021018100A patent/BR112021018100A2/pt unknown
- 2020-03-09 US US17/439,293 patent/US20220152107A1/en active Pending
- 2020-03-09 CA CA3133736A patent/CA3133736A1/en active Pending
- 2020-03-09 JP JP2021555590A patent/JP2022524882A/ja active Pending
- 2020-03-09 EP EP20757209.0A patent/EP3940063A2/en active Pending
- 2020-03-09 MX MX2021011120A patent/MX2021011120A/es unknown
- 2020-03-09 AU AU2020242520A patent/AU2020242520B2/en active Active
- 2020-03-09 KR KR1020217033073A patent/KR20220012224A/ko unknown
- 2020-03-09 SG SG11202109574Q patent/SG11202109574QA/en unknown
- 2020-03-09 WO PCT/CU2020/050002 patent/WO2020187340A2/es unknown
- 2020-03-09 EA EA202192447A patent/EA202192447A1/ru unknown
- 2020-03-12 TW TW109108199A patent/TW202102667A/zh unknown
- 2020-03-13 AR ARP200100724A patent/AR118369A1/es unknown
-
2021
- 2021-09-30 CO CONC2021/0013127A patent/CO2021013127A2/es unknown
- 2021-10-13 ZA ZA2021/07758A patent/ZA202107758B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020242520A1 (en) | 2021-11-11 |
TW202102667A (zh) | 2021-01-16 |
CO2021013127A2 (es) | 2022-03-18 |
ZA202107758B (en) | 2022-12-21 |
EA202192447A1 (ru) | 2021-12-07 |
WO2020187340A2 (es) | 2020-09-24 |
AU2020242520B2 (en) | 2024-04-04 |
CA3133736A1 (en) | 2020-09-24 |
US20220152107A1 (en) | 2022-05-19 |
CN113785048A (zh) | 2021-12-10 |
KR20220012224A (ko) | 2022-02-03 |
EP3940063A2 (en) | 2022-01-19 |
BR112021018100A2 (pt) | 2022-02-08 |
CU20190021A7 (es) | 2020-10-20 |
MX2021011120A (es) | 2022-01-18 |
JP2022524882A (ja) | 2022-05-10 |
SG11202109574QA (en) | 2021-10-28 |
WO2020187340A3 (es) | 2021-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR118369A1 (es) | Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva | |
Bonnetain et al. | Statistical challenges in the analysis of health-related quality of life in cancer clinical trials | |
ECSP18041733A (es) | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación | |
EA202090931A2 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
MX2019006374A (es) | Receptores inmunes sinteticos y metodos de usos de ellos. | |
WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
AR109771A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CL2016000376A1 (es) | Anticuerpos anti-prlr y sus usos | |
MX2019015021A (es) | Metodo de fabricacion de anticuerpos biespecificos, anticuerpos biespecificos y uso terapeutico de dichos anticuerpos. | |
MY186337A (en) | Cd123 binding agents and uses thereof | |
MX2019015349A (es) | Anticuerpos biespecificos para receptor 1 huerfano tipo receptor de tirosina cinasa (ror1) y grupo de diferenciacion 3 (cd3). | |
CL2008001335A1 (es) | Compuestos derivados de pirrolopirimidin-7-ona, antagonistas de los receptores de purina p2x; porceso de preparacion de estos; composicion farmaceutica que los comprende; proceso de preparacion de compuestos intermediarios y usos en el tratamientos del dolor, vejiga hiperactiva, entre otras. | |
BR112013005145A2 (pt) | anticorpos anti-cxcl13 e métodos para seu uso | |
BR112021019411A2 (pt) | Métodos para a produção de células car-nk e uso das mesmas | |
AR095555A1 (es) | Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf) | |
BR112022000876A2 (pt) | Anticorpos imunomoduladores e métodos de uso destes | |
CO2022007238A2 (es) | Terapia de células t del receptor de antígeno quimérico | |
CL2020000734A1 (es) | Expansión y uso de fracciones de células nk ampliadas. | |
MX2021008796A (es) | Anticuerpos contra subunidad alfa il-7r y usos de estos. | |
EA201992875A1 (ru) | T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения | |
WO2019133454A3 (en) | Methods to improve the therapeutic index of activated t cells | |
Munthali et al. | YES I DO. Initiation ceremonies in Traditional Authority Liwonde in Machinga District in Southern Malawi | |
BR112018012223A2 (pt) | membrana de camada única, métodos de fabrico de uma membrana e de preparação de um tecido biológico reconstruído, dispositivo de cultura celular, utilização in vitro da membrana, tecido biológico reconstruído e utilização de um tecido biológico reconstruído | |
Filz et al. | Prostir radity camp as an example of the treatment concept of secure transitional holding space and digression in case of PTSD and GAD | |
FUKAHORi | Investigation Regarding the Properties of Protein Kinase Cθ Selective Inhibitor as a Novel T cell Immunosuppressant |